WallStreetZenWallStreetZen

NASDAQ: GTBP
Gt Biopharma Inc Stock

$3.00+0.02 (+0.67%)
Updated Jun 13, 2024
GTBP Price
$3.00
Fair Value Price
$0.76
Market Cap
$4.25M
52 Week Low
$2.61
52 Week High
$14.37
P/E
-0.43x
P/B
0.8x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$9.64M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.87
Operating Cash Flow
-$10M
Beta
0.62
Next Earnings
Jun 25, 2024
Ex-Dividend
N/A
Next Dividend
N/A

GTBP Overview

GT Biopharma, Inc. is a clinical-stage biopharmaceutical companydeveloping immuno-oncology products based on its proprietary Tri-specific Killer Engager fusion protein immune cell engager technology platform. Known as OXIS International, Inc. until 2017, GT Biopharma was incorporated in 1965 and is based in Brisbane, CA.

Zen Score

Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how GTBP scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

GTBP ($3.00) is overvalued by 296% relative to our estimate of its Fair Value price of $0.76 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
GTBP ($3.00) is not significantly undervalued (296%) relative to our estimate of its Fair Value price of $0.76 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
GTBP is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more GTBP due diligence checks available for Premium users.

Be the first to know about important GTBP news, forecast changes, insider trades & much more!

GTBP News

Valuation

GTBP fair value

Fair Value of GTBP stock based on Discounted Cash Flow (DCF)
Price
$3.00
Fair Value
$0.76
Overvalued by
296.00%
GTBP ($3.00) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
GTBP ($3.00) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
GTBP is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

GTBP price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-0.43x
Industry
-7.95x
Market
30.48x

GTBP price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
0.8x
Industry
6.3x
GTBP is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

GTBP's financial health

Profit margin

Revenue
$0.0
Net Income
-$2.3M
Profit Margin
0%
GTBP's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials

Assets to liabilities

Assets
$9.9M
Liabilities
$4.6M
Debt to equity
0.87
GTBP's short-term assets ($9.89M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
GTBP's short-term assets ($9.89M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
GTBP's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
GTBP's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$4.2M
Investing
$5.0M
Financing
$0.0
GTBP's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

GTBP vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
GTBP$4.25M+0.67%-0.43x0.80x
PALI$4.26M+1.79%-0.19x0.42x
ARTL$4.29M0.00%-0.42x0.45x
CING$4.19M-1.00%-0.03x1.30x
AZTR$4.18M-3.97%0.18x0.97x

Gt Biopharma Stock FAQ

What is Gt Biopharma's quote symbol?

(NASDAQ: GTBP) Gt Biopharma trades on the NASDAQ under the ticker symbol GTBP. Gt Biopharma stock quotes can also be displayed as NASDAQ: GTBP.

If you're new to stock investing, here's how to buy Gt Biopharma stock.

What is the 52 week high and low for Gt Biopharma (NASDAQ: GTBP)?

(NASDAQ: GTBP) Gt Biopharma's 52-week high was $14.37, and its 52-week low was $2.61. It is currently -79.12% from its 52-week high and 14.94% from its 52-week low.

How much is Gt Biopharma stock worth today?

(NASDAQ: GTBP) Gt Biopharma currently has 1,416,651 outstanding shares. With Gt Biopharma stock trading at $3.00 per share, the total value of Gt Biopharma stock (market capitalization) is $4.25M.

Gt Biopharma stock was originally listed at a price of $846.60 in Mar 27, 2018. If you had invested in Gt Biopharma stock at $846.60, your return over the last 6 years would have been -99.65%, for an annualized return of -60.95% (not including any dividends or dividend reinvestments).

How much is Gt Biopharma's stock price per share?

(NASDAQ: GTBP) Gt Biopharma stock price per share is $3.00 today (as of Jun 13, 2024).

What is Gt Biopharma's Market Cap?

(NASDAQ: GTBP) Gt Biopharma's market cap is $4.25M, as of Jun 15, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Gt Biopharma's market cap is calculated by multiplying GTBP's current stock price of $3.00 by GTBP's total outstanding shares of 1,416,651.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.